Abiopharma

🔍 Smith Michael Alexander (Executive)

Company: INSMED Inc (INSM)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 12,780 shares of Common Stock at $30.46 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 79,174.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,354 shares of Common Stock at $141.16 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 77,820.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,100 shares of Common Stock at $142.06 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 76,720.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 7,391 shares of Common Stock at $143.16 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 69,329.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 8,300 shares of Common Stock at $144.16 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,029.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 4,944 shares of Common Stock at $145.18 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 56,085.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 1,183 shares of Common Stock at $145.89 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,902.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 12,780 shares of Stock Option (right to buy) at $30.46 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2028-01-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F8

Footnotes:

• F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F2: This is the weighted average sales price representing 1,354 shares sold at prices ranging from $140.58 to $141.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F3: This is the weighted average sales price representing 1,100 shares sold at prices ranging from $141.58 to $142.55 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F4: This is the weighted average sales price representing 7,391 shares sold at prices ranging from $142.70 to $143.63 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F5: This is the weighted average sales price representing 8,300 shares sold at prices ranging from $143.72 to $144.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F6: This is the weighted average sales price representing 4,944 shares sold at prices ranging from $144.72 to $145.57 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F7: This is the weighted average sales price representing 1,183 shares sold at prices ranging from $145.75 to $146.04 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F8: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
• REMARKS: Exhibit List - Exhibit 24 - Power of Attorney